Pazopanib and Statin-Induced Rhabdomyolysis
| Autor: | Bahram Kiani, Rhonda L. Bitting, Jennifer M. Logue |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
Statin medicine.drug_class Urology Case Report 030204 cardiovascular system & hematology lcsh:RC254-282 Rhabdomyolysis Metastasis Pazopanib Rosuvastatin 03 medical and health sciences 0302 clinical medicine Renal cell carcinoma medicine 030212 general & internal medicine business.industry Cancer medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Discontinuation Hyperlipidemia Oncology Cytochrome p450 business medicine.drug VEGF inhibitor |
| Zdroj: | Case Reports in Oncology Case Reports in Oncology, Vol 10, Iss 3, Pp 954-957 (2017) |
| ISSN: | 1662-6575 |
| Popis: | Background: The VEGF inhibitor pazopanib is a widely used first-line therapy for the treatment of advanced renal cell carcinoma. Potential drug-drug interactions and toxicities may be underrecognized. Case Presentation: A 73-year-old woman with metastatic renal cell carcinoma on treatment with pazopanib presented with progressive inability to ambulate. The initial concern was for metastasis to the spine. However, MRI of the spine revealed diffuse muscle edema with no metastatic deposits or lytic lesions. Upon further evaluation, creatine kinase was significantly elevated and the diagnosis of rhabdomyolysis was made. With aggressive hydration and discontinuation of both pazopanib and rosuvastatin, the patient made a full recovery. Conclusion: This case of drug-induced rhabdomyolysis demonstrates an unexpected toxicity resulting from concomitant pazopanib and rosuvastatin therapy. This combination is predicted to be safe due to different, nonoverlapping effects on the cytochrome p450 enzymes. Discontinuation of statin therapy in patients with metastatic cancer should be considered when the risk of cancer-related death exceeds the risk of cardiovascular-related death. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|